Hemodynamic effects of sildenafil citrate and isosorbide mononitrate in men with coronary artery disease and erectile dysfunction - PubMed (original) (raw)
Randomized Controlled Trial
Hemodynamic effects of sildenafil citrate and isosorbide mononitrate in men with coronary artery disease and erectile dysfunction
Graham Jackson et al. J Sex Med. 2005 May.
Abstract
Introduction: Mild hemodynamic effects have been reported with sildenafil citrate therapy.
Aim: To compare the hemodynamic effects of sildenafil and isosorbide mononitrate (ISMN) in men with coronary artery disease and erectile dysfunction.
Methods: A total of 31 men aged 35 years or older with coronary artery disease (at least 50% narrowing of the left main stem or at least 70% narrowing of any other coronary artery) and erectile dysfunction (receiving medication for erectile dysfunction or scoring less than 26 out of a maximum score of 30 on the erectile function domain questions of International Index of Erectile Function) were randomized to sildenafil 100 mg (n = 10), ISMN 40 mg (n = 11), or placebo (n = 10) in this single-dose multicenter study.
Main outcome measures: Hemodynamic parameters were measured at baseline, 1, 2, 4, and 6 hours post dose.
Results: Compared with baseline, cardiac index increased slightly with sildenafil (0.29 L/min/m2 at 1 hour) and decreased slightly with placebo (-0.12 L/min/m2 at 4 hours) and ISMN (-0.14 L/min/m2 at 1 hour). The stroke volume index increased from baseline at each time point post dose with sildenafil (4.4 mL/m2 at 2 hours), but decreased with ISMN (-5.8 mL/m2 at 1 hour) and placebo (-2.8 mL/m2 at 4 hours). ISMN reduced mean arterial pressure more than sildenafil did (-22 vs. -10 mm Hg at 2 hours, respectively). Both sildenafil and ISMN increased heart rate (4 vs. 7 beats/minute at 1 hour, respectively) and decreased systemic vascular resistance, but sildenafil produced greater reductions in pulmonary vascular resistance. There were no serious adverse events in the sildenafil group.
Conclusions: Sildenafil 100 mg was well tolerated and induced smaller changes in central and peripheral hemodynamic pressures compared with ISMN 40 mg. Moreover, sildenafil selectively reduced pulmonary resistance, which may have clinical importance in pulmonary hypertension.
Similar articles
- Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina.
Webb DJ, Muirhead GJ, Wulff M, Sutton JA, Levi R, Dinsmore WW. Webb DJ, et al. J Am Coll Cardiol. 2000 Jul;36(1):25-31. doi: 10.1016/s0735-1097(00)00705-1. J Am Coll Cardiol. 2000. PMID: 10898408 Clinical Trial. - Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: a randomized crossover trial.
Arruda-Olson AM, Mahoney DW, Nehra A, Leckel M, Pellikka PA. Arruda-Olson AM, et al. JAMA. 2002 Feb 13;287(6):719-25. doi: 10.1001/jama.287.6.719. JAMA. 2002. PMID: 11851538 Clinical Trial. - Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist.
Webb DJ, Freestone S, Allen MJ, Muirhead GJ. Webb DJ, et al. Am J Cardiol. 1999 Mar 4;83(5A):21C-28C. doi: 10.1016/s0002-9149(99)00044-2. Am J Cardiol. 1999. PMID: 10078539 Clinical Trial. - Coronary and systemic hemodynamic effects of sildenafil citrate: from basic science to clinical studies in patients with cardiovascular disease.
Gillies HC, Roblin D, Jackson G. Gillies HC, et al. Int J Cardiol. 2002 Dec;86(2-3):131-41. doi: 10.1016/s0167-5273(02)00421-7. Int J Cardiol. 2002. PMID: 12419549 Review. - [Sex, erectile dysfunction, and the heart: a growing problem].
Görge G, Flüchter S, Kirstein M, Kunz T. Görge G, et al. Herz. 2003 Jun;28(4):284-90. doi: 10.1007/s00059-003-2478-8. Herz. 2003. PMID: 12825143 Review. German.
Cited by
- Acute cardiac and hemodynamic effects of sildenafil on resistant hypertension.
Quinaglia T, de Faria AP, Fontana V, Barbaro NR, Sabbatini AR, Sertório JT, Demacq C, Tanus-Santos JE, Moreno H. Quinaglia T, et al. Eur J Clin Pharmacol. 2013 Dec;69(12):2027-36. doi: 10.1007/s00228-013-1571-z. Epub 2013 Aug 21. Eur J Clin Pharmacol. 2013. PMID: 23963046 Clinical Trial. - Effectiveness and safety of phosphodiesterase 5 inhibitors in patients with cardiovascular disease and hypertension.
Chrysant SG. Chrysant SG. Curr Hypertens Rep. 2013 Oct;15(5):475-83. doi: 10.1007/s11906-013-0377-9. Curr Hypertens Rep. 2013. PMID: 23917809 Review. - The pleiotropic effects of phosphodiesterase 5 inhibitors on function and safety in patients with cardiovascular disease and hypertension.
Chrysant SG, Chrysant GS. Chrysant SG, et al. J Clin Hypertens (Greenwich). 2012 Sep;14(9):644-9. doi: 10.1111/j.1751-7176.2012.00669.x. Epub 2012 Jun 7. J Clin Hypertens (Greenwich). 2012. PMID: 22947364 Free PMC article. Review. - Bicycle riding, perineal trauma, and erectile dysfunction: data and solutions.
Goldstein I, Lurie AL, Lubisich JP. Goldstein I, et al. Curr Urol Rep. 2007 Nov;8(6):491-7. doi: 10.1007/s11934-007-0054-0. Curr Urol Rep. 2007. PMID: 18042330 Review. - Angiogenesis and improved cerebral blood flow in the ischemic boundary area detected by MRI after administration of sildenafil to rats with embolic stroke.
Li L, Jiang Q, Zhang L, Ding G, Gang Zhang Z, Li Q, Ewing JR, Lu M, Panda S, Ledbetter KA, Whitton PA, Chopp M. Li L, et al. Brain Res. 2007 Feb 9;1132(1):185-92. doi: 10.1016/j.brainres.2006.10.098. Epub 2006 Dec 26. Brain Res. 2007. PMID: 17188664 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical